OBJECTIVE: Aberrant DNA methylation is an early event in carcinogenesis which could be leveraged to detect ovarian cancer (OC) in plasma. METHODS: DNA from frozen OC tissues, benign fallopian tube epithelium (FTE), and buffy coats from cancer-free women underwent reduced representation bisulfite sequencing (RRBS) to identify OC MDMs. Candidate MDM selection was based on receiver operating characteristic (ROC) discrimination, methylation fold change, and low background methylation among controls. Blinded biological validation was performed using methylated specific PCR on DNA extracted from independent OC and FTE FFPE tissues. MDMs were tested using Target Enrichment Long-probe Quantitative Amplified Signal (TELQAS) assays in pre-treatment plasma from women newly diagnosed with OC and population-sampled healthy women. A random forest modeling analysis was performed to generate predictive probability of disease; results were 500-fold in silico cross-validated. RESULTS: Thirty-three MDMs showed marked methylation fold changes (10 to >1000) across all OC subtypes vs FTE. Eleven MDMs (GPRIN1, CDO1, SRC, SIM2, AGRN, FAIM2, CELF2, RIPPLY3, GYPC, CAPN2, BCAT1) were tested on plasma from 91 women with OC (73 (80%) high-grade serous (HGS)) and 91 without OC; the cross-validated 11-MDM panel highly discriminated OC from controls (96% (95% CI, 89-99%) specificity; 79% (69-87%) sensitivity, and AUC 0.91 (0.86-0.96)). Among the 5 stage I/II HGS OCs included, all were correctly identified. CONCLUSIONS: Whole methylome sequencing, stringent filtering criteria, and biological validation yielded candidate MDMs for OC that performed with high sensitivity and specificity in plasma. Larger plasma-based OC MDM studies, including testing of pre-diagnostic specimens, are warranted.
OBJECTIVE: Aberrant DNA methylation is an early event in carcinogenesis which could be leveraged to detect ovarian cancer (OC) in plasma. METHODS: DNA from frozen OC tissues, benign fallopian tube epithelium (FTE), and buffy coats from cancer-free women underwent reduced representation bisulfite sequencing (RRBS) to identify OC MDMs. Candidate MDM selection was based on receiver operating characteristic (ROC) discrimination, methylation fold change, and low background methylation among controls. Blinded biological validation was performed using methylated specific PCR on DNA extracted from independent OC and FTE FFPE tissues. MDMs were tested using Target Enrichment Long-probe Quantitative Amplified Signal (TELQAS) assays in pre-treatment plasma from women newly diagnosed with OC and population-sampled healthy women. A random forest modeling analysis was performed to generate predictive probability of disease; results were 500-fold in silico cross-validated. RESULTS: Thirty-three MDMs showed marked methylation fold changes (10 to >1000) across all OC subtypes vs FTE. Eleven MDMs (GPRIN1, CDO1, SRC, SIM2, AGRN, FAIM2, CELF2, RIPPLY3, GYPC, CAPN2, BCAT1) were tested on plasma from 91 women with OC (73 (80%) high-grade serous (HGS)) and 91 without OC; the cross-validated 11-MDM panel highly discriminated OC from controls (96% (95% CI, 89-99%) specificity; 79% (69-87%) sensitivity, and AUC 0.91 (0.86-0.96)). Among the 5 stage I/II HGS OCs included, all were correctly identified. CONCLUSIONS: Whole methylome sequencing, stringent filtering criteria, and biological validation yielded candidate MDMs for OC that performed with high sensitivity and specificity in plasma. Larger plasma-based OC MDM studies, including testing of pre-diagnostic specimens, are warranted.
Authors: Bradley W Anderson; Yun-Suhk Suh; Boram Choi; Hyuk-Joon Lee; Tracy C Yab; William R Taylor; Brian A Dukek; Calise K Berger; Xiaoming Cao; Patrick H Foote; Mary E Devens; Lisa A Boardman; John B Kisiel; Douglas W Mahoney; Seth W Slettedahl; Hatim T Allawi; Graham P Lidgard; Thomas C Smyrk; Han-Kwang Yang; David A Ahlquist Journal: Clin Cancer Res Date: 2018-05-29 Impact factor: 12.531
Authors: Graham P Lidgard; Michael J Domanico; Janelle J Bruinsma; James Light; Zubin D Gagrat; Rebecca L Oldham-Haltom; Keith D Fourrier; Hatim Allawi; Tracy C Yab; William R Taylor; Julie A Simonson; Mary Devens; Russell I Heigh; David A Ahlquist; Barry M Berger Journal: Clin Gastroenterol Hepatol Date: 2013-04-29 Impact factor: 11.382
Authors: Thomas F Imperiale; David F Ransohoff; Steven H Itzkowitz; Theodore R Levin; Philip Lavin; Graham P Lidgard; David A Ahlquist; Barry M Berger Journal: N Engl J Med Date: 2014-03-19 Impact factor: 91.245
Authors: Laia Piqué; Alexia Martinez de Paz; David Piñeyro; Anna Martínez-Cardús; Manuel Castro de Moura; Pere Llinàs-Arias; Fernando Setien; Jorge Gomez-Miragaya; Eva Gonzalez-Suarez; Stefan Sigurdsson; Jon G Jonasson; Alberto Villanueva; August Vidal; Veronica Davalos; Manel Esteller Journal: Oncogene Date: 2019-08-13 Impact factor: 9.867
Authors: Mariana Brait; Shizhang Ling; Jatin K Nagpal; Xiaofei Chang; Hannah Lui Park; Juna Lee; Jun Okamura; Keishi Yamashita; David Sidransky; Myoung Sook Kim Journal: PLoS One Date: 2012-09-27 Impact factor: 3.240
Authors: Saundra S Buys; Edward Partridge; Amanda Black; Christine C Johnson; Lois Lamerato; Claudine Isaacs; Douglas J Reding; Robert T Greenlee; Lance A Yokochi; Bruce Kessel; E David Crawford; Timothy R Church; Gerald L Andriole; Joel L Weissfeld; Mona N Fouad; David Chia; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Patricia Hartge; Paul F Pinsky; Claire S Zhu; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; Jian-Lun Xu; Philip C Prorok; John K Gohagan; Christine D Berg Journal: JAMA Date: 2011-06-08 Impact factor: 157.335
Authors: Hio Chung Kang; Jong In Kim; Hee Kyung Chang; Gavitt Woodard; Young Sik Choi; Ja-Lok Ku; David M Jablons; Il-Jin Kim Journal: Sci Rep Date: 2016-09-28 Impact factor: 4.379